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Abstract
Background: Genome-scale CRISPR interference (CRISPRi) has been used in human cell lines; however, the features
of effective guide RNAs (gRNAs) in different organisms have not been well characterized. Here, we define rules that
determine gRNA effectiveness for transcriptional repression in Saccharomyces cerevisiae.
Results: We create an inducible single plasmid CRISPRi system for gene repression in yeast, and use it to analyze
fitness effects of gRNAs under 18 small molecule treatments. Our approach correctly identifies previously described
chemical-genetic interactions, as well as a new mechanism of suppressing fluconazole toxicity by repression of the
ERG25 gene. Assessment of multiple target loci across treatments using gRNA libraries allows us to determine
generalizable features associated with gRNA efficacy. Guides that target regions with low nucleosome occupancy
and high chromatin accessibility are clearly more effective. We also find that the best region to target gRNAs is
between the transcription start site (TSS) and 200 bp upstream of the TSS. Finally, unlike nuclease-proficient Cas9
in human cells, the specificity of truncated gRNAs (18 nt of complementarity to the target) is not clearly superior
to full-length gRNAs (20 nt of complementarity), as truncated gRNAs are generally less potent against both
mismatched and perfectly matched targets.
Conclusions: Our results establish a powerful functional and chemical genomics screening method and provide
guidelines for designing effective gRNAs, which consider chromatin state and position relative to the target gene
TSS. These findings will enable effective library design and genome-wide programmable gene repression in many
genetic backgrounds.
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Background
The bacterial type II CRISPR (clustered regularly inter-
spaced palindromic repeats) associated Cas9 nuclease can
be targeted to DNA using an engineered guide RNA
(gRNA), enabling genome editing in a variety of organisms
[1–4]. The Cas9 protein can be further modified to act as
a programmable effector. Two point mutations can yield a
catalytically dead Cas9 (dCas9) [3] which alone can serve
as an effective programmable transcriptional repressor in
bacteria [5]. With further modification, dCas9 can be
made to function as a transcription activator or repressor
(aka CRISPR interference, or CRISPRi) capable of modu-
lating gene expression in eukaryotes [6–10], including in
Saccharomyces cerevisiae [6, 7]. One of the advantages of
CRISPR/Cas9 over previous methods of genome engineer-
ing such as Transcription Activator Like Effector Nucle-
ases (TALENs) and Zinc Fingers is the compatibility of
the specificity-determining region of the gRNA (generally
20 bases in length) with highly-parallel array-based oligo-
nucleotide synthesis. Thus, large libraries of gRNAs can
be readily synthesized and cloned for functional gen-
omic or genome editing applications. Several groups
have taken advantage of this, and generated genome-
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wide libraries for knocking out [11–14], silencing [15],
and activating genes [15, 16].
The tremendous potential of the CRISPR/Cas9 system
has motivated efforts to better understand factors that
influence its efficacy. Gilbert et al. [15] characterized the
ideal genomic region to target gRNAs for effective re-
pression in K562 human myeloid leukemia cells. They
found CRISPRi worked best using gRNAs that direct
dCas9-KRAB to a window of -50 bp to +300 bp relative
to the transcription start site (TSS) of a gene, with a
maximum effect observed in the 50-100 bp region just
downstream of the TSS [15]. It is currently not known if
these rules for guide positioning apply to other cell lines
or organisms. Further, not all gRNAs targeted to this
window functioned equally well, and therefore additional
factors likely influence efficacy.
Understanding and limiting the off-target activity of
CRISPR/Cas9 is also important for most applications of
the system. Several groups have demonstrated that
CRISPR/Cas9 can tolerate some mismatches between
the gRNA and the target, indicating potential to cut or
bind unintended sites [10, 17–21]. One strategy that has
proven effective in preventing off-target cutting in hu-
man HEK293 and U2OS cells is to truncate the gRNA’s
region of target site complementarity from 20 nt to
17 nt or 18 nt [20, 22]. The specificity of these truncated
gRNAs has only been tested in human cells, however,
and only with nuclease-proficient Cas9.
Here, we present a versatile platform for high-
throughput characterization of CRISPR/Cas9 gRNA li-
braries in Saccharomyces cerevisiae. Informed by existing
chemical-genomic data, we designed and tested gRNAs
directed to 20 genes whose expression was predicted to
influence sensitivity to specific small molecule inhibitors
of growth. Repression of these genes by dCas9-Mxi1 in-
deed produced quantifiable and drug-specific growth de-
fects, which we then used to assess a variety of factors
potentially influencing efficacy and specificity. We evalu-
ated the effect of genome position, chromatin accessibil-
ity, nucleosome and transcription factor occupancy of
the target site, as well as the length, sequence, and sec-
ondary structure of the gRNA. While our major goal
was to determine rules predictive of CRISPR/Cas9 func-
tion in yeast, our experiments also revealed surprising
biological insights, including a novel cellular mechanism
for resistance to the antifungal drug fluconazole. Collect-
ively, our results advance the development of CRISPRi
as a powerful approach for functional genomics.
Results
Single plasmid system for CRISPR interference in yeast
We designed and constructed a plasmid for regulatable
CRISPRi in yeast (Fig. 1). The plasmid is a derivative of
pRS416 [23], which contains a yeast centromeric origin
of replication and a URA3 selectable marker. To this
backbone, we added the complete open reading frame
(ORF) for catalytically inactive Streptococcus pyogenes
Cas9 (dCas9) to which the Mxi1 transcriptional repres-
sor was fused at the C-terminus [6]. We also added the
tetracycline repressor (tetR) ORF, a tetO-modified RPR1
RNA polymerase III promoter [7, 24], a NotI restriction
site, and common gRNA sequence. The NotI site en-
ables rapid cloning of short oligonucleotides encoding
the target complementarity region of the RNA guide. In
this system, TetR and dCas9-Mxi1 are constitutively
expressed from the GPM1 and TEF1 promoters, respect-
ively, whereas the gRNA is inducibly expressed by
addition of anhydrotetracycline (ATc) to the growth
medium (Fig. 1b).
To validate this system as a rapid and versatile ap-
proach for transcriptional silencing in yeast, we designed
gRNAs targeting the ERG11, ERG25, CRG1, and SEC14
genes. Previous work has demonstrated that these four
genes are haploinsufficient in the presence of the small
molecule inhibitors fluconazole, 1181-0519, cantharidin,
and 4130-1276 [25, 26], respectively. Thus, we reasoned
that transcriptional repression by dCas9-Mxi1 should
produce a growth defect in the presence of the appropri-
ate chemical compound. Based on previous small scale
studies [7], guides targeting regions near the TSS of each
gene were synthesized, and inserted into the NotI site of
our expression construct (Methods). The growth rates of
transformants were then measured in increasing concen-
trations of the appropriate compounds, in both the pres-
ence and absence of ATc (Methods). In all four cases,
and as expected, ATc-induced expression of the gRNA
resulted in increased small molecule sensitivity relative
to the empty-vector control (Fig. 1c, Additional file 1).
We characterized the system further and showed that
ATc-dependent repression was titratable by addition of in-
creasing concentrations of ATc to the culture (Additional
file 2: Figure S1). Quantitative PCR (qPCR) analysis of
transcript levels revealed rapid repression within ap-
proximately 2.5 h following ATc addition, but slow re-
versibility. Repression levels varied among the gRNAs
assayed with the most effective gRNA repressing tran-
scription roughly 10-fold. Even though we observed
modest ATc-independent small molecule sensitivity for
one of four gRNAs (CRG1) in Fig. 1c (possibly indicat-
ing leaky expression), qPCR analysis of CRG1 transcript
levels did not reveal significant gene repression in the
non-induced (-ATc) condition (Additional file 2: Figure
S1, Additional file 3). Thus, the collective data are con-
sistent with strong transcriptional control of the guide.
High-throughput CRISPRi via gRNA library screening
Akin to the DNA barcodes used for the yeast deletion
collection [27, 28], the short specificity-determining
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Fig. 1 a Schematic of expression construct for regulatable CRISPRi in yeast. Key features include ORFs expressing dCas9-Mxi1 and the tetracycline
repressor (TetR), as well as a tetracycline inducible gRNA locus containing the RPR1 promoter with a TetO site, a NotI site for cloning new gRNA
sequences encoding target complementarity, and the constant part of the gRNA. b In the absence of anhydrotetracycline (ATc) TetR binds the
gRNA promoter and prevents PolIII from binding and transcribing the gRNA. This in turn prevents dCas9-Mxi1 from binding the target site. In the
presence of ATc, TetR dissociates and gRNA is expressed, allowing dCas9-Mxi1 to bind its target locus, and repress gene expression. c CRISPRi-induced
drug-sensitivity. Transformants expressing gRNAs directed against CRG1, ERG11, ERG25, and SEC14 (indicated above each panel), were grown in the
presence of a specific small molecule (that is, cantharidin, fluconazole, 1181-0519, and 4130-1276, respectively). Growth of the gRNA-expressing strain
and the empty vector control, was measured in the presence and absence of ATc (see legend). Growth relative to the ‘no-drug’ control is indicated on
the y-axis (see Methods), in increasing concentrations of each small molecule (x-axis)
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regions of gRNAs (that is, the sequence complementary
to the target) can act as unique identifiers of individual
strains. Like barcodes, these can be readily quantified
using next-generation sequencing [29, 30], thereby enab-
ling high-throughput strain phenotyping following com-
petitive growth in pooled cultures. By taking advantage
of this, and inexpensive array-based oligonucleotide
DNA synthesis, we sought to establish a quantitative
assay for guide efficacy, with the goal of uncovering
generalizable rules for effective use of CRISPRi in yeast
(Additional file 2: Figure S2). In total, we created and
tested five gRNA libraries comprised of a total of 989
unique gRNAs (Additional file 4), in the presence of
various small molecule inhibitors of growth (Additional
file 5). The guide counts following competitive growth
were highly reproducible between biological replicates, in-
dicating that the assay is robust (Additional file 2: Figure
S3A-B, Additional files 6 and 7).
We first tested a library (that is, the ‘gene_tiling20’ li-
brary) of 238 guides targeting protospacer adjacent motif
(PAM)-containing positions (on both the template and
nontemplate strands) between 150 bp upstream of the
TSS and +50 bp relative to the ORF start of 20 different
genes. These 20 genes included the four described in
Fig. 1c, and 16 others that have a specific small molecule
partner that when added to a culture at the correct dose,
will render that gene haploinsufficient [25]. Repression
of a target gene is expected to increase sensitivity to its
specific small molecule partner, but in general, not to other
compounds under study. We leveraged this “reference set”
of chemical genetic interactions (Additional file 8) to
benchmark the assay and assess gRNA efficacy.
All but one (CRG1) of the genes targeted by the
‘gene_tiling20’ library are essential for viability. Consist-
ent with effective repression of an essential gene, several
guides exhibited fewer sequencing reads following growth
in the presence of ATc, compared to that in the absence of
ATc (Fig. 2a). Notably, however, the majority of gRNAs
targeting the 19 essential genes did not elicit a growth
phenotype. Raw sequence read information, and the ATc-
induced fold change (A; see Methods) of each gRNA, are
listed in Additional files 9 and 10, respectively.
We challenged this library with 18 different small
molecules from our reference set (Additional file 8), and
consistently observed that addition of a small molecule
to the culture increased the number of gRNAs causing
growth defects. Specifically, in addition to those gRNAs
that inhibit growth by virtue of their potent repression
of an essential gene, additional gRNAs targeting genes
known to be haploinsufficient for the added compound
became depleted following competitive growth (Additional
file 2: Figure S4A). For example, although no guides
directed against the essential gene ERG11 inhibited growth
(median-adjusted A < -1) under standard conditions, six
ERG11 guides produced growth defects when yeast were
cultured in 20 μM fluconazole, an antifungal drug that
inhibits the Erg11 protein (Fig. 2b). These results were rep-
resentative of the other compounds tested. In each case,
the addition of compound increased assay sensitivity,
allowing the effects of guides that only weakly modulate
transcription to be detected (Fig. 2b). Nonetheless, not all
guides produced a growth defect even when induced in the
presence of their partner small molecule. Factors influen-
cing guide efficacy are explored in detail later in the
manuscript.
Exploring small molecule mechanism-of-action
To specifically explore small molecule mechanism of
action (MoA), we calculated the ‘drug-specific effect’
(D; see Methods) on each strain by comparing induced
(+ATc) cultures grown in the presence of a small mol-
ecule, to those grown without the small molecule. This
drug-induced fold change metric identifies only those
genes that are dosage sensitive to the test compound.
These genes are powerful descriptors of a compound’s
MoA. For example, comparing relative guide counts
following growth +/- 20 μM fluconazole primarily iden-
tifies strains in which ERG11 is repressed as sensitive to
fluconazole (Fig. 2c). Moreover, ERG11-repressor strains
were, for the most part, not affected by the other com-
pounds assayed (Fig. 2d). These results were representa-
tive of the other, previously-defined, chemical-genetic
interactions that comprised our reference set (Additional
file 11, Additional file 2: Figure S4B-C).
Collective analysis of strains expressing gRNAs di-
rected against the same gene further verified that the
small molecules tested specifically affected strains pre-
dicted by our reference set (Fig. 2e, Additional file 12).
Interestingly, however, we also observed several exam-
ples where a small molecule affected the growth of a
strain not predicted beforehand (off-diagonal red signal
in Fig. 2e). As this figure reports the average drug-
specific effect (D) on strains in a set, off-target binding
by gRNAs is an unlikely explanation for the unexpected
signal. Indeed, several lines of evidence suggest many
represent bona fide chemical-genetic interactions. In
cases where the same compound was tested at multiple
concentrations, these interactions were reproducible and
dose-dependent. The compound 9125678 was particu-
larly interesting, as it inhibited growth of strains in
which ERG11, ERG13, and ERG25 were repressed. All
three genes encode components of the yeast ergosterol
pathway, suggesting a mechanism of action to be tested
in future experiments.
We also found that the growth-inhibitory effects of
fluconazole were reduced in multiple ERG25-repressor
strains, suggesting that ERG25 repression confers resist-
ance to fluconazole. Growth assays in isogenic cultures
































































































































































































































Fig. 2 Parallel analysis of CRIPSRi-induced fitness defects in pooled cultures. a Effect of gRNA expression on growth. gRNA sequencing counts following
growth in induced (+ATc) vs. uninduced (-ATc) conditions were used to calculate the ATc-effect (A0) for each gRNA, which were median-centered and
plotted on the y-axis. Each point represents a gRNA directed against one of 20 different target genes (gene_tiling20 library). gRNAs are color-coded and
arranged alphabetically on the x-axis by target gene. In the plot, A0 values below -4 were set to -4. b Effect of small molecules on detecting
gRNA-induced growth defects. For each gene target (x-axis), the number of gRNAs inducing a growth defect (median-centered A < -1) in
standard conditions, and in the presence of its paired reference small molecule is plotted on the y-axis (see legend). c Fluconazole-specific growth defects
(y-axis) are plotted for each gRNA (x-axis), which are color-coded and arranged alphabetically by target gene. The drug/gene pair representing the
reference chemical-genetic interaction is highlighted in gray. d Drug-specific effects for the ERG11 gRNA set in 25 different drug conditions (x-axis). Points
are color-coded by condition. Large black dots represent the mean in each drug condition, and are colored red if >1 or if < -1. In c and d, drug-specific
effect (D) values below -4 were set to -4. e Heatmap illustrating the average drug-specific effect for each guide set (y-axis), in each condition (x-axis). A
guide set refers to the group of guides directed against the same gene. Drug-sensitivity is indicated in red, drug-resistance in blue. Previously defined
chemical-genetic interactions are arranged on the diagonal and are outlined in green. Triangles above indicate cases where the same compound was
assayed at increasing concentrations
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confirmed this observation (Fig. 3a, Additional file 13).
Similar results were obtained via chemical inhibition of
the Erg25 protein with 1181-0519. This compound,
predicted by metabolomic profiling to inhibit Erg25
(Additional file 2: Figure S5 and Additional file 14),
increased growth of the control strain (BY4741) in the
presence of fluconazole (Fig. 3b). Interestingly, CRISPRi-
mediated repression of ERG25 caused an approximately
2.5-fold increase in ERG11 transcript levels, thus
providing a likely explanation for the observed flucona-
zole resistance (Additional file 2: Figure S1B and S1D,
Additional file 3).
Efficacy and specificity of full-length and truncated gRNAs
Having validated our overall approach and reference
set, we next evaluated factors influencing gRNA per-
formance. To this end, we focused on the growth in-
hibitory effects of gRNAs specifically in the presence
of their partner chemical compound. Experiments in
human cell lines have demonstrated that off-target
cutting by Cas9 can be mitigated by reducing the
length of the gRNA’s target complementarity from
20 nt, to either 17 or 18 nt [20, 22]. To assess effects
of gRNA length on CRISPRi in yeast, we created an
18 nt version of our gene_tiling20 library described
above (gene_tiling18), and assayed it under the same
conditions. The growth effects resulting from both
versions of each gRNA were generally consistent, with
full-length and truncated versions of a gRNA often
exhibiting similar effects (Fig. 4a). We found, how-
ever, that full-length gRNAs tended to produce stron-
ger phenotypes more often: for example, 94 of 182
full-length but only 73 of 182 truncated gRNAs re-
sulted in growth defects (gRNA effect < -2, solid gray
lines in Fig. 4a).
To compare the specificity of gRNAs with 18 nt and
20 nt of target complementarity, we selected a single
functional guide for ERG11, ERG25, CRG1, and SEC14,
and designed a series of derivatives containing one,
two, or three mismatches to the target sequence (24 in
total for each target gene, for both truncated and full-
length gRNAs). gRNA-induced sensitivity to the appro-
priate small molecule was assayed and, as expected, ex-
pression of the ‘perfect’ gRNA resulted in sensitivity
(Fig. 4b, Additional file 2: Figure S6. As previously re-
ported [17, 18, 21], we found that mismatches located
in the seed region (that is, positions 1-10 relative to
the PAM) were poorly tolerated by both full-length
and truncated gRNAs (Fig. 4b, Additional file 2: Fig-
ure S6). In general, gRNAs containing mismatches in
this region had reduced efficacy (that is, they did not
yield growth defects), while mismatches in the distal
region (positions 11-20) had little influence on effi-
cacy. Plotting the effects of full-length and truncated
gRNAs against each other (Fig. 4c) revealed that
gRNAs with 20 nt of complementarity tended to be
more effective repressors than those with 18 nt. Im-
portantly however, this was true of both the perfect
and mismatched gRNAs. Thus, considering their re-
duced efficacy against perfectly matching target se-
quences, truncated gRNAs did not exhibit a marked
improvement in specificity compared to their full-length
counterparts.
gRNA efficacy depends on accessibility and location of
the target region
As illustrated above, different gRNAs directed against
the same gene can have a range of efficacies (Fig. 2a-d).
We tested whether the effective target window reported
for CRISPRi in human cell lines contributes to this vari-
ability [15]. To do so, we created a library of 383 full-
length guides targeting -500 bp to +500 bp of the TSS
region of five genes (broad_tiling library), and challenged
this library with four chemical compounds. Combining
these data with those from the gene_tiling20 library
above, we found that the median guide effect was max-
imal in the window of -200 bp to TSS, while guides
downstream of the TSS, or further than 300 bp upstream
of the TSS were less effective (Fig. 5a). Effective repres-
sion outside the -200 bp to TSS window did occur, but
less frequently.
The asymmetry of guide effectiveness around the
TSS, and the variability between closely positioned
guides indicate that absolute distance to the TSS is
not the only determinant of efficacy. As yeast pro-
moters are known to be nucleosome-free, with strictly
positioned nucleosomes following the TSS [31–33],
we hypothesized that chromatin accessibility and nu-
cleosome occupancy play a role in guide efficacy. We
extracted nucleosome occupancy and average chroma-
tin accessibility scores from yeast ATAC-seq data
[34], and plotted these data with guide effects in
Fig. 5b. A positive relationship between chromatin ac-
cessibility and gRNA efficacy was most apparent for
the SEC14 and SSL2 loci. We next systematically
quantified the influence of accessibility on guide effi-
cacy. In the TSS -400 bp to TSS +400 bp window,
guides targeting nucleosome-free and ATAC-seq
accessible regions were more effective (Fig. 5c). The
relationship with ATAC-seq read density persists in
the typically nucleosome-occupied region of TSS to
TSS +400 bp, suggesting that accessibility influences
efficacy independently of positioning relative to the TSS
(Additional file 2: Figure S7A). Similar results were ob-
tained when our data were compared to other genome-
wide nucleosome position data [33] (Additional file 2:
Figure S7B and Additional file 15).
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We tested a range of additional potential determinants
of guide efficacy (Additional file 16). We first considered
the sequence context of the target and found no specific
base pairs that were significantly correlated with gRNA
efficacy (Additional file 2: Figure S8). Next, we used data
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Fig. 3 Erg25 regulates fluconazole sensitivity. a Strains containing gRNA constructs directed against ERG3, ERG11, ERG25, and the empty vector
control (indicated above each panel), were grown in 63.1 μM fluconazole, in either the presence (blue), or absence of 250 ng/μL ATc (red). In each panel,
optical density (OD) is plotted on the y-axis, as a function of time on the x-axis. Loss of ERG3 function was previously shown to confer fluconazole resistance
[55, 56] and served as a positive control. b Similar to (a). The parental BY4741 strain was grown in 60 μM fluconazole (red), 60 μM fluconazole + 40 μM
1181-0519 (blue), or no drug (black)
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whose known or inferred presence in the target region is
correlated with guide potency. We found a small num-
ber of cases where overlap with a transcriptional activa-
tor binding site correlated with stronger guide effects
(Additional file 17). Finally, we did not observe a strong ef-
fect of RNA secondary structure or melting temperature
on gRNA efficacy (Additional file 2: Figure S9).
Our results primarily identify position relative to the
TSS and chromatin state as important determinants of
whether a gRNA will enable robust transcriptional re-
pression by dCas9. For example, 39 % (171/442) of full-
length gRNAs (which targeted regions +/-500 bp from
the TSS) exhibited effective repression (gRNA effect < -2)
in our assay. On the other hand, gRNAs that target the
200 bp region immediately upstream of the TSS and a
nucleosome-depleted region, were effective 76 % (59/78)
of the time. Even though additional factors may determine
whether a specific gRNA will be a strong transcriptional
A
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Fig. 4 Quantitative comparison of full-length and truncated gRNAs. a gRNA effects (see methods) of 182 full-length gRNAs (20 nt of complementarity
to the target) are plotted on the y-axis, and their truncated counterparts (18 nt of complementarity) on the x-axis. In all cases, gRNA-expressing strains
were grown in the appropriate reference small molecule. Dotted and solid gray lines demarcate gRNA effects of 0 and -2, respectively. b Heatmaps
illustrating growth defects induced by gRNAs containing different mismatches to the target sequence. Full-length and truncated gRNAs are arranged
by target gene on the y-axis. The reference small molecule is labeled on the right. The mismatch position of each gRNA relative to the PAM is
indicated on the x-axis (gRNAs matching the target sequence perfectly are on the far left). Missing values are indicated with an X. c As in (a),
only the mismatched gRNAs described in (b) are plotted. Points are color-coded based on target gene (see legend). Large points represent
the ‘perfect’ gRNAs, all other points represent gRNAs containing mismatches.
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modulator, applying these two criteria will likely improve
performance of future gRNA libraries. We have created a
webtool (http://lp2.github.io/yeast-crispri/) to enable rapid
design of gRNAs for effective CRISPRi in yeast.
Discussion
We demonstrated that CRISPRi with inducible gRNA
expression is a useful and effective tool to repress genes
in yeast. In particular, CRISPRi provides a good alterna-
tive to other approaches for studying essential genes
[36–39]. CRISPRi constructs can be readily transformed
into existing knock-out, GFP-tagged, or other collec-
tions, thus enabling genome-wide effects of repressing a
particular gene to be characterized. We further showed
that CRISPRi, paired with complex gRNA libraries, can








































































Fig. 5 Effect of target location and accessibility on gRNA efficacy. In all plots gRNA efficacy was measured in the presence of the appropriate
reference small molecule. a gRNA effect magnitude (absolute value of gRNA effects that were censored to have a maximum of 0) is plotted on
the y-axis, against target position relative to the TSS on the x-axis. The median in 50 bp windows (solid line, big markers), overlapping by 25 bp,
indicates a region of 200 bp immediately upstream the TSS as effective. b gRNA effect magnitude is plotted on the y-axis, against target position
(gRNA midpoint) relative to the TSS on the x-axis for four loci (indicated above each plot). gRNAs targeting template and non-template strands
are indicated with ‘o’ and ‘x’, respectively. Standard deviation estimates are indicated with blue lines, and maximum estimated gRNA effect magnitude
for each target locus is given as a gray dashed line. Nucleosome occupancy (red line), and smoothed ATAC-seq read density (green line) relative to the
region maximum are scaled to the maximum effect magnitude. c gRNA effects (y-axis) are plotted (black dots) against nucleosome occupancy score
(x-axis, left) and ATAC-seq read density (x-axis, right). The median of gRNA effects in windows of 0.25, overlapping by 0.125, is indicated by the circular
blue markers. The blue bars show the first and third quartiles. The Spearman correlation for the relationship with nucleosome density is 0.34, P value =
9.6 × 10-12. The Spearman correlation for the relationship with normalized ATAC-Seq is -0.35, P value = 2.2 × 10-12
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or chemical genomic screens. Additionally, CRISPRi plas-
mid libraries can easily be transformed into any number
of different strain backgrounds.
Consistent with CRISPRi being specific for the intended
target, increased small molecule sensitivity of gene knock-
down strains was largely confined to the predicted gene/
drug combinations (Fig. 2c, d and Additional file 2: Figure
S4B, S4C). We also analyzed our gRNAs for possible sites
of off-target binding using ECRISP [40], and found very
few sites that could potentially result in a growth defect
(by repression of an essential gene), and none in the TSS
region of the 20 genes we focused on (Additional file 18).
Nevertheless, it is difficult to know if, or to what extent,
off-target binding occurred in our experiments. By
employing multiple guides directed against the same tar-
get however, one can be more confident that phenotypes
observed with multiple independent guides are due to
repression of the intended target and not off-target repres-
sion. Using this strategy, we uncovered and confirmed a
novel chemical-genetic interaction, where Erg25 repres-
sion results in resistance to the common antifungal drug,
fluconazole.
In our yeast data, truncated gRNAs do not greatly re-
duce mismatch tolerance when used with the dCas9-Mxi1
repressor. This result is inconsistent with the findings
from human cell lines using nuclease-proficient Cas9
[20, 22], and implies one of several possibilities. First,
truncated gRNAs could be effective in reducing mis-
match tolerance in human cells, but not in yeast. Alter-
natively, mismatched truncated guides may reduce
Cas9’s ability to cleave when compared to equivalent
mismatched full length guides, but not its ability to
bind to target sequences. dCas9-Mxi1 may only need to
bind to the target site to induce transcriptional repres-
sion. It is therefore possible that nuclease-proficient
Cas9 is still recruited to mismatched target sites by
truncated gRNAs but is no longer able to cleave its tar-
get. Further studies are required to test these hypoth-
eses. Additionally, we observed that truncated gRNAs
that are a perfect match to their target are generally
less potent than their full-length counterparts. Thus,
we found no clear advantage in using truncated guides
for CRISPRi in S. cerevisiae.
Our results on ideal guide positioning also differ from
those found in human cell lines in which the optimal
window for CRISPRi was found to be downstream of the
TSS in the 5’UTR [15]. In yeast, we found the optimal
window to be a 200 bp region immediately upstream of
the TSS. While this difference could be due to the differ-
ent repressors used (Mxi1 vs KRAB), it could also reflect
differences in chromatin structure between yeast and
mammalian cells [41, 42]. We observed strong and sta-
tistically significant links between guide efficacy and nu-
cleosome occupancy, as well as chromatin accessibility.
Nucleosome positioning will likely affect gRNA function
in other organisms, and thus successful gRNA design is
likely to be species- and even locus-specific. Indeed,
ChIP-seq analysis of dCas9 binding in mammalian cells
has shown that dCas9 is more likely to bind off-target
sites in open chromatin regions than in closed chroma-
tin [21]. Our study thus defines simple design rules tak-
ing these correlates into account that will increase the
likelihood of gRNAs having a potent repressive effect.
Conclusions
We have established a powerful functional and chemical
genomics screening platform using the CRISPR/Cas9
system for targeted transcriptional repression in S. cere-
visiae. A reference set of chemical-genetic interactions
enabled sensitive measurement of gRNA efficacy at mul-
tiple loci. Most notably, we found that truncated gRNAs
generally exhibited reduced efficacy towards both mis-
matched and perfectly matched target sequences com-
pared to their full-length counterparts. In addition, we
identify nucleosome occupancy as a major determinant
of gRNA performance. gRNAs directed to a region be-
tween the TSS and 200 bp upstream of the TSS were
more likely to be effective. These findings will directly
enable library design and genome-wide screening in
yeast, and may also inform the application of CRISPRi in
other organisms.
Methods
Plasmid and strain construction
All primers, strains, and plasmids used in this study are
listed in Additional file 19. All chemical compounds
used in this study are listed in Additional file 8. Molecu-
lar cloning was done with Gibson Assembly as outlined
in Gibson et al. [43]. E. coli minipreps were performed
with QIAprep Spin Minipreps (Qiagen). Preparation of
competent E. coli DH5α and transformation used Zymo
Mix & Go E. coli Transformation reagents and Zymo
Broth. Hifi Hotstart (Kapa Biosystems), Q5 (NEB) and
Phusion Hot Start Flex (Thermo Scientific) high fidelity
polymerases were used for PCRs. Primers and single
gRNA oligonucleotides were ordered from IDT. gRNA
oligo libraries were ordered from Custom Array. DpnI
treatment was used to remove template plasmids in PCRs
that were followed by Gibson Assembly. Benchling.com
DNA editing software was used for plasmid design. Indi-
vidual constructs (not libraries) were sequenced by Sanger
Sequencing (Sequetech).
To build the dCas9 repressor, we first modified pRS414-
Tef1-Cas9-Cyc1t obtained from addgene [1] to introduce
the D10A and H840A mutations to produce dCas9. We
also fused a nuclear localization signal to the N terminus
of dCas9. The human Mxi1 domain and linker from [6]
was then fused to the C terminal of dCas9.
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We built our single plasmid system in the yeast pRS414
and pRS416 Cen/ARS plasmids containing the Trp1 and
Ura3 markers, respectively. First, we introduced an engi-
neered Tet inducible pRPR1 PolIII promoter [7, 24, 44],
NotI site, and gRNA sequence, as well as the Tet repressor
(TetR) gene under control of the GPM1 promoter and ter-
minator into pRS414-Tef1-NLS-dCas9-Mxi1-Cyc1 at the
PciI site adjacent to the ori using Gibson Assembly. These
vectors are referred to as pRS41XgT. We then PCRed the
gRNA and TetR and cloned them into pRS416 digested
with PciI along with a bridging oligo to correct the PciI
site cut in Ura3. Next we PCRed and cloned the Tef1-
NLS-dCas9-Mxi1-Cyc1 section of the plasmid into this
vector. We are providing our tet-inducible CRISPRi plas-
mid on AddGene for other investigators to study their
questions of interest.
gRNA oligos were amplified with extender oligos that
produced 40 bp overlaps on either side of the region of
target complementarity, and then cloned into the NotI
site with Gibson Assembly. The same protocol was ap-
plied both to individual oligos and libraries of oligos.
These were then transformed into DH5α cells and plated
on LB-agar containing carbenicillin. For individual clones,
single colonies were obtained and screened by colony
PCR and Sanger sequencing. Correct colonies were cul-
tured and plasmids extracted. For libraries, all colonies
were washed off plates with LB-Carb liquid and then
minipreped.
Competent S. cerevisiae (strain BY4741) were prepared
either by standard lithium acetate transformation protocols
or using Frozen-EZ Yeast Transformation II Kit™ (Zymo
Research). Transformed cells were selected on synthetic
complete media (SCM) – Ura agar plates. For individ-
ual strains, single colonies were selected for additional
experiments. For library preparation, all colonies were
washed off plates with SCM-Ura liquid media, vor-
texed, and aliquoted into 25 % glycerol stocks of 3.0
ODs of cells each for later use.
Growth assays of individual strains
Strains were grown overnight in synthetic complete media
lacking uracil (SCM-Ura). Growth assays were performed
in 96 well NUNC flat bottom plates in 100 μL SCM–Ura
cultures. Starting OD600 was either OD600 0.01 or 0.03,
but was consistent within individual experiments. Growth
rates were determined by measuring the OD600 approxi-
mately every 15 min for at least 80 cycles at 30 °C in
TECAN sunrise or GENios plate readers. Drugs were
dissolved in DMSO and dispensed to plates using an HP
D300 Digital Dispenser (Tecan). The growth rate of a
strain was calculated as follows:(1) the first 10 OD readings
were averaged and subtracted from all OD readings of the
corresponding curve in order to set the baseline of the
growth curve to zero; (2) the area under the curve (AUC)
was then calculated as the sum of all OD readings. ‘Relative
growth’ was calculated as previously described [45], and as
follows: (AUCcondition – AUCcontrol)/AUCcontrol; where
AUCcontrol represents the growth rate of the reference con-
dition that was assayed on the same microtiter plate.
qPCRs
For qPCR experiments, strains were typically cultured in
SCM–Ura media overnight, diluted to an OD/mL of
0.15 in the presence (or absence) of 250 ng/mL ATC,
grown further, and samples collected at the times indi-
cated. For the ATc removal time course, cells were
washed five times with sterile water to remove any
residual ATc. RNA was extracted from samples using
the Ambion RiboPure™ RNA Purification Kit for yeast
(Life Technologies), or the Quick RNA Kit (Zymo
Research). RNA was converted to cDNA using the High-
Capacity RNA-to-cDNA™ Kit (Life Technologies). This
cDNA was diluted 1:10 and then used for SYBR qPCR.
qPCR primers were designed using primer3 to give prod-
ucts of approximately 75-150 bases in length (Additional
file 19). Real time/qPCR was performed using SYBR® Green
PCR Master Mix (Life Technologies) and the Applied Bio-
systems 7900HT Fast Real-Time PCR System running SDS
V2.3. The gRNAs used for these experiments are listed
in Additional file 19. Log2 fold change relative to a ref-
erence condition was calculated as the negative delta
delta Ct (-DDCt) as follows: DDCt = ((average Ct)gene-
(average Ct)control gene) in test condition – ((average
Ct)gene – (average Ct)control gene) in reference condition.
Average Ct values were typically calculated from four
replicates. Standard deviation (StdDev) was calculated
as the square root of ((StdDev of Ctgene)
2 + (StdDev of
Ctcontrol gene)
2) as measured in the test condition.
Library design
The ‘gene tiling’ libraries were designed to a window of
150 bp upstream of the TSS to 50 bp into the ORF. TSS
were specified as the most common transcript start pos-
ition from transcript isoform profiling data [46], or in-
ferred to be a fixed distance of 27 bp upstream of the
start codon based in part on previous results [47]. Ex-
cluding 41/442 guides targeting genes without transcript
isoform profiling support for the TSS, did not affect the
results (Additional file 2: Figure S10). A full list of genes
examined are available in Additional file 8. Guides were
designed both to the template strand and non-template
strand. For each of these guides we designed versions
containing 18 nt and 20 nt of target complementarity
(gene_tiling18 and gene_tiling20, respectively). Even
though gRNAs were designed for CDC12, ERO1, and
RPO21, small molecule inhibitors specific to these genes
were not assayed. For five of the genes (ERG11, ERG25,
SEC14, CRG1, and SSL2) we designed all possible full-
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length guides within a window of 500 bp up- and down-
stream of the TSS (broad_tiling).The mutant library was
designed by taking the sequences for four gRNAs we
had previously shown to be functional and making a
random single base change for all positions in the seed
sequence (1-10) as well as in positions 11, 12, 14, and
16. For each guide, we synthesized both an 18 and 20 nt
version (mutant18 and mutant20, respectively). We used
ECRISP version 4.2 to look for potential off-target bind-
ing sites in the yeast genome, allowing for up to two
mismatches.
Competitive growth assays
Prior to setting up experiments, aliquots of a library
were recovered in YPD media for 4 h, and then diluted
appropriately for the experiments. Yeast culturing and
sample collection was performed using a cell-screening
platform that integrates temperature-controlled absorb-
ance plate readers, plate coolers, and a liquid handling
robot. Briefly, 700 μL yeast cultures were grown (+/- a
drug listed in Additional file 8, and +/- ATc) in 48 well
plates at 30 °C with orbital shaking in Infinite plate
readers (Tecan). To maintain cultures in log phase over
many doublings, 23 μL of the culture was removed when
it reached an OD of 0.76, added to a well containing
700 μL of media, and then allowed to grow further. After
three such dilutions, 600 μL of the culture was collected
and saved to a 4 °C cooling station (Torrey Pines) when it
reached an OD of 0.76. This amounted to approximately
20 culture doublings from the beginning of the experi-
ment. Pipetting events were triggered automatically by
Pegasus Software and performed by a Freedom EVO
workstation (Tecan).
A key parameter in this protocol is the extent to which a
drug inhibits growth of the pool. In general, drug concen-
trations that inhibit growth by approximately 20 % are best
for identifying chemical-genetic interactions and yielding
reproducible results. If a drug was observed to inhibit the
pool’s growth too strongly (for example, by >50 %), the ex-
periment was repeated using a lower drug concentration.
After sample collection, yeast plasmids were purified
using the Zymoprep Yeast Plasmid Miniprep II kit
(Zymo Research). Purified plasmids were used as a tem-
plate for PCR with barcoded up- and down-sequencing
primers that produce a double index to uniquely identify
each sample. PCR products were confirmed by agarose
gel electrophoresis. After PCR, samples were combined
and bead cleaned with Thermo Scientific™ Sera-Mag
Speed Beads Carboxylate-Modified particles. Sequencing
was performed using Illumina MiSeq.
Metabolite extraction and GCMS analysis
Our previously described methods were used for metab-
olite measurement [48]. In brief, yeast pellets of six
biological replicates were homogenized in 1× PBS buffer
with 0.5 mg of 0.5 mm glass beads/tube by vortexing for
a total of 6 min. Every 2 min between vortexing, the
tubes were returned back to ice. The homogenized mix-
ture was extracted by Folch method [49]. The lower
phase of the chloroform:methanol:water mixture, con-
taining the sterol metabolites extracted from the yeast
cell pellet, was collected and dried in a Speedvac. The
samples were derivatized by MSTFA + 1 % TMCS and
analyzed by Agilent 7200 series GC/Q-TOF. The sterols
were separated on HP5-MS UI column (30 m, 0.25 mm
i.d, 0.25 μm film thickness) at split ratio 20:1 using he-
lium as carrier gas at 1 mL/min. The oven temperature
program was as follows: 60 °C held for 1 min, then oven
temperature was ramped at 10 °C/min to 325 °C where
it was held for 3.5 min. Data were collected at acquisi-
tion rate of 5 Hz in both profile and centroid modes.
Qualitative and quantitative analysis was performed
using Agilent MassHunter Workstation.
Ergosterol, lansterol, and methoxyamine hydrochlor-
ide were purchased from Sigma. HPLC grade metha-
nol, chloroform, and water were from Honeywell
Burdick and Jackson. The derivatization reagent
MSTFA (N-methyl-N-trimethylsilytrifluoroacetamide)
with 1 % TMCS (trimethylchlorosilane) was from
Thermo Fisher Scientific (Bellefonte, PA, USA).
Sequence data analysis
We used a combination of established tools and custom
python pipelines to quantify gRNA effects from the se-
quence data. First, we created a synthetic reference
chromosome sequence for each of the expected ampli-
cons. The synthetic reference included Illumina adap-
tors, library barcode, PCR amplification priming region,
PCR barcode, and the gRNA region complementary to
the target. As the forward and reverse reads were
expected to overlap given the sequencing read length,
and average 190 bp amplicon length, we merged the
reads using PEAR [50] version 0.9.4 with default param-
eters. The resulting FastQ file was mapped against the
created synthetic reference using BWA [51] version
0.6.1-r104 with command line ‘bwa index [reference];
bwa aln -n3 -o3 -e1 -l22 [reference] [fastq] > [aln]; bwa
samse -f [out] [reference] [aln] [fastq]’. This parameter
setting allows for three mismatches, three gaps, one
large gap, and short 22 bp seed sequences. For each of
the expected amplicons, we counted the number of per-
fect matches (flag NM:i:0) from the resulting alignments
(Additional file 9, column ‘Count_perfect’) that were
used in subsequent analyses.
Guide fitness calculation
We quantified fitness f for guide i in pool j, condition k
as the relative growth rate fijk. For a guide with cijk
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counts in condition k, we calculated the log2-scale me-
dian centered counts lijk = log2(cijk + 0.5) - mediani’ in pool
j(log2(ci’jk + 0.5)). As any such count statistics are highly
variable at low abundances, it is important to also record
the confidences of this value. We calculated the empir-
ical variance estimate of lijk by resampling reads given
the total library size of Cjk reads, and Nj guides in pool j
condition k. To do so, we inferred the posterior read fre-
quency in the pool as Gamma(cijk + 0.5, Cjk + 0.5Nj),
sampled 1,000 observations of read counts, calculated
the log-scale median centered count for each, and used
the variance s2ijk of the simulated values as a variance
estimate for the log scale counts. In the following, we




To estimate the guide effect on growth, we calculated the
ATc-induced fold change (A). For conditions k + and k-
(with and without ATc, respectively), we infer the ATc-
induced fold change Aijk on guide i in pool j as the differ-
ence in the fitness between the cultures with and without





the control condition (1 % DMSO), we had eight replicate
experiments for the tiling pools, and three replicate exper-
iments for 20 μM fluconazole. We combined the R repli-
cates k1,…,kR in a natural way to obtain the variance
var(Aijk) = 1/(1/var(Aijk1) +… + 1/var(AijkR)), and mean <
Aijk > = var(Aijk) * (<Aijk1>/var(Aijk1) +… + <AijkR>/var(-
AijkR)). The combined estimate across replicates is then
Aijk ~Normal(<Aijk>, var(Aijk)). gRNAs with fewer than 30
reads following growth in the minus ATc control condi-
tion were excluded from this analysis, as their effect size
estimates had large variance across conditions.
The ATc-induced fold change (A) of a gRNA, calcu-
lated following growth in the presence of its specific
partner reference compound (Additional file 8), was de-
fined as the ‘gRNA effect’ or ‘guide effect’ and used in
Figs. 4, 5c, Additional file 2: Figure S6, and S7. In cases
where we tested multiple concentrations of a reference
compound, we selected data from one concentration
(these are indicated in Additional file 8). For the plots in
Fig. 5a, b, and Additional file 2: Figure S9, we first
restrict A values to have a maximum of 0, and then take
the absolute value of this. We define this as the ‘gRNA
effect magnitude’. This calculation is based on the rea-
sonable assumption that repression of the target gene
can only result in drug-sensitivity (that is, a negative
ATc-induced fold change), and that any apparent resist-
ance (that is, positive ATc-induced fold change) is a
result of technical noise in a poorly functional gRNA.
Drug-specific effect estimation
To estimate the drug-specific effect D for guide i in pool j
and drug k, we contrasted the guide fitness with and
without drug when the system was induced with ATc, that





condition k = 0 is the 1 % DMSO control, and its parame-
ters are for the distribution inferred from the eight repli-
cates. gRNAs having fewer than 30 reads following growth
in the presence of ATc, but without additional chemical
compound, were excluded from this analysis, as their
effect size estimates had large variance across conditions.
Guide melting temperature calculation
We used ViennaRNA package 2.0 (RNAfold version
2.1.9 ViennaRNA Package 2.0) [52] to calculate RNA
folding and duplex formation energies for the entire tar-
geting region, as well as the eight nucleotide seed, and
the oligotm [53] library, both with default parameters.
ATAC-seq and nucleosome data
We downloaded the nucleosome occupancy and ATAC-
seq insertion data from Schep et al. [34] in bigWig format,
and converted it to wig using UCSC utilities (./bigWig
ToWig < input > < output > -chrom = < chromosome > -
start = < TSS-1000 > -end = < TSS + 1000 >). For each
nucleotide, we used the per-base.wig output as the
measure of nucleosome occupancy, and the average
ATAC-seq insert count in 51 base window centered on
the base as the ATAC-seq signal. Spearman correlation
was calculated using the spearmanr function in the
scipy.stats python package.
We also compared the efficacy of gRNAs targeting
ERG11, ERG25, SEC14, and SSL2 to yeast nucleosome
occupancy measurements reported by Lee et al. [33].
Based on previous exonuclease footprinting experiments
[54], we first defined a genomic region predicted to be
occupied by dCas9 upon successful base pairing with the
gRNA. This region (or ‘window’) consisted of the gen-
omic target sequence recognized by the gRNA, plus
three bases on either end. Window coordinates were de-
fined based on the February 2006 SGD genome build as
these data were used in the analysis by Lee et al. [33].
We downloaded log2 ratios representing the relative
hybridization signal of total genomic DNA to nucleo-
somal DNA. These measurements were made using a
4 bp resolution tiling array of the yeast genome, and
therefore, each gRNA has 6 or 7 log2 values within its
window. These values were averaged to generate the
‘Nucleosome Occupancy’ values plotted for each gRNA
in Additional file 2: Figure S7B, which were compared to
the effects of gRNAs for ERG11, ERG25, SEC14, and
SSL2; R and P values (Spearman correlation) were calcu-
lated in Spotfire (Perkin Elmer).
Target sequence context
We considered the region of 20 bp upstream of the
PAM to 20 bp downstream of the end of the target
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sequence. For each site in this region, and each of A, C,
G, T bases, we calculated the relative gRNA effect in
control condition for all the guides whose target se-
quence has that base at the considered site. Relative
gRNA effect was calculated by dividing the gRNA effect
for each guide by the maximum gRNA effect con-
strained to be between 0 and -6 for each control drug/
gene set. We calculated the P value of the median effect
as the fraction of 10,000 random samples of same num-
ber of overlapping guides that have at least as large me-
dian effect. We also report P values Bonferroni-
corrected for the number of tests (4 bases × 63 sites =
252 tests).
Overlap with transcription factor binding sites
We downloaded data from Reimand et al. [35], as used
in Zaugg and Luscombe [31]. We considered three levels
of overlap - sites overlapping middle of the specificity-
determining sequence, middle 10 bases of the sequence,
and any part of the sequence. For each factor, and each
level of overlap, we calculated the mean guide effect
magnitude in control condition of all the overlapping
guides in gene_tiling20 and broad_tiling guide sets. For
each level, we only considered factors that overlapped at
least 10 guides. We calculated the P value of the median
effect as the fraction of 10,000 random samples of same
number of overlapping guides that have at least as large
mean effect. We also report P values Bonferroni-corrected
for the number of tests.
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